Today's leading physicians leave nothing to chance when it comes to ensuring responsible patient decisions. Advances in the application of genetic information means accessing critical insights into issues such as drug side effects and effectiveness, disease diagnosis and other critical clinical decisions—before you take action.
Start making better decisions through DNA with Companion Dx—and put Pre-actionary Medicine to work today.
7000 Fannin, Suite 1880A
Houston, TX 77030
832.538.1600
888.482.5327
info@companiondxlab.com
Partners | |||
|---|---|---|---|
 |
Companion Dx offers QIAGEN’s FDA-approved therascreen® KRAS RGQ PCR Kit, which provides guidance on the use of Erbitux® (certuximab) as a treatment in patients with metastatic colorectal cancer. |  |
Companion Dx is part of a non-exclusive licensing agreement with Epigenomics for its DNA methylation biomarker Septin9—used in the development and commercialization ofa blood-based laboratory-developed test for detecting colorectal cancer. |
 |
Companion Dx is one of 22 certified test centers in the U.S. for Roche’s FDA approved cobas® 4800 BRAF V600 Mutation Test—an in vitro diagnostic device intended to be used as an aid in selecting melanoma patients whose tumors carry the BRAF V600E mutation for treatment with Zelboraf® tests. |  |
|